The lack of association of this mTORC1-dependent phosphorylation event with response to LY3009120 further supports the differentiation of the effects of RAF inhibitors on preclinical CRC models as compared to preclinical melanoma models, where sensitivity to BRAF- and MEK-specific inhibitors was positively correlated with a decrease in pS6 phosphorylation [25, 41]. The gene discussed is RAF1; the disease is melanoma.